BioNexus Gene Lab Corp. Business Acquisition, Pro Forma Net Income (Loss)
BioNexus Gene Lab Corp. (BGLC) reported Business Acquisition, Pro Forma Net Income (Loss) of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2021-05-18
- BioNexus Gene Lab Corp. business acquisition, pro forma net income (loss) for the quarter ending 2021-03-31 was $0.00.
- BioNexus Gene Lab Corp. business acquisition, pro forma net income (loss) for the quarter ending 2020-03-31 was -$346.01K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month |
|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-18 |
| 2020-03-31 | -$346.01K 10-Q · filed 2021-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |